[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529596":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":45,"locations":55,"responsibleParty":71,"collaborators":73,"id":77,"slug":29,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":29,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":29,"overallStatus":58,"whyStopped":29,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University Hospital, Ghent","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"CFA\u002FPPOS cycle","EXPERIMENTAL","Interventional stimulation",[13,14,15,16],"Drug: Elonva®","Drug: Puregon®","Drug: Gonapeptyl®","Drug: Cerazette®",{"label":18,"type":19,"description":20,"interventionNames":21},"rFSH \u002F GnRH antagonist cycle","ACTIVE_COMPARATOR","Conventional stimulation",[14,22,15],"Drug: Orgalutran®",[24,30,34,37,41],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Elonva®","Single injection",[9],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Puregon®","Multiple injections",[9,18],{"type":25,"name":35,"description":32,"armGroupLabels":36,"otherNames":29},"Orgalutran®",[18],{"type":25,"name":38,"description":39,"armGroupLabels":40,"otherNames":29},"Gonapeptyl®","Double injection",[9,18],{"type":25,"name":42,"description":43,"armGroupLabels":44,"otherNames":29},"Cerazette®","Oral tablet",[9],[46,51],{"name":47,"role":48,"phone":49,"phoneExt":29,"email":50},"Dominic Stoop, Prof. dr.","CONTACT","093321699","Dominic.Stoop@uzgent.be",{"name":52,"role":48,"phone":53,"phoneExt":29,"email":54},"Kathleen Wijnant, Msc","+32(0)93323013","Kathleen.Wijnant@uzgent.be",[56],{"facility":57,"status":58,"city":59,"state":29,"zip":60,"country":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"University Hospital Ghent","RECRUITING","Ghent","9000","Belgium",{"type":63,"coordinates":64},"Point",[65,66],3.71667,51.05,{"lat":66,"lon":65},[69,70],{"name":47,"role":48,"phone":29,"phoneExt":29,"email":50},{"name":52,"role":48,"phone":29,"phoneExt":29,"email":54},{"type":72,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[74],{"name":75,"class":76},"Organon","INDUSTRY","100529596",false,"NCT06175832","PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study","PPOS and CFA for Elective Freeze-all Ovarian Stimulation Cycles: a Prospective Cross-over Study","P-CCROSS","Prescreening: Clarification: Pre-screening might be performed to identify women with AFC \\> 5 and AMH \\> 1.1 ng\u002Fml (Bologna criteria, AFC and AMH values are valid for one year).\n\nInclusion criteria for:\n\n* Group 1: indication for oocyte cryopreservation\n* Group 2: indication for IVF\u002FICSI and PGT-A\n\nInclusion criteria for both groups:\n\n* First ovarian stimulation cycle\n* Aged ≥ 18 and \\\u003C 41 years old at the time of first OPU\n\nExclusion Criteria:\n\n* contra-indication for ovarian stimulation\n* expected poor ovarian response (Bologna Criteria)\n* PCOS patients\n* refusal to fill out questionnaires before, during and after treatment\n* simultaneous participation in another clinical study\n* untreated and uncontrolled thyroid dysfunction;\n* current use of oral contraceptives, anti-psychotics, anti-epileptics or chemotherapy;\n* pregnant or breastfeeding women. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.","FEMALE","18 Years","40 Years",{"count":88,"type":89},60,"ESTIMATED","INTERVENTIONAL",[92],"PHASE4","P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH\u002FGnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA\u002FPPOS versus rFSH\u002FGnRH ovarian stimulation cycles.",[95,96,97,98],"Ovarian Stimulation","Quality of Life","Preimplantation Genetic Testing","Fertility Preservation","2025-12-18",{"date":101,"type":102},"2025-12-26","ACTUAL",{"date":104,"type":102},"2025-01-27",{"date":106,"type":89},"2027-12-31",{"name":5,"class":6},1]